Legal & General Group PLC Landos Biopharma, Inc. Transaction History

Legal & General Group PLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 22, 2022	SELL	$0.6 - $1.5 $244 - $612	-408 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$9.77 - $15.77 $1,768 - $2,854	-181 Reduced 30.73%	408 $6,000
Q1 2021 May 17, 2021	BUY	$9.47 - $16.26 $5,577 - $9,577	589 New	589 $6,000

Ticker LABP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,254,900
Description
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of u...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.